Experimental HCV Drugs
Experimental HCV Drugs
DDW2014: Coverage of Digestive Disease Week 2014
- Details
- Category: HBV Treatment
- Published on Saturday, 31 May 2014 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 2014 Digestive Disease Week annual meeting (DDW 2014) in Chicago, May 3-6, 2014.
Hepatitis C
New Hepatitis C Treatments Highlighted at Digestive Disease Week
Some Negative Predictive Factors Do Not Impair Response to Faldaprevir
AbbVie Interferon-free Regimen Cures More than 90% of Hepatitis C Patients
Sustained Response to Interferon Is Durable in Children with Hepatitis C
HIV/HCV Coinfection
Some Negative Predictive Factors Do Not Impair Response to Faldaprevir
Hepatitis B
Outcomes in HBV/HCV Coinfected People Depend on Which Virus Dominates
Some Hepatitis B Patients Can Stop Antiviral Treatment Without Relapse
Complications and Related Conditions
Rifaximin May Be Beneficial for People with Advanced Liver Cirrhosis
Drinking More Coffee Is Associated with Less Liver Fibrosis
DDW 2014: Some Negative Predictive Factors Do Not Impair Response to Faldaprevir
- Details
- Category: Experimental HCV Drugs
- Published on Sunday, 18 May 2014 00:00
- Written by Liz Highleyman
Some factors traditionally associated with poorer response to interferon-based therapy for hepatitis C played little role in clinical trials of the HCV protease inhibitor faldaprevir, according to several studies presented at Digestive Disease Week this month in Chicago. HCV subtype 1a and prior treatment did not significantly worsen response, while HIV/HCV coinfection may be associated with better response.
Janssen Seeks Approval of Simeprevir + Sofosbuvir for HCV Genotype 1
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 12 May 2014 00:00
- Written by Janssen
Janssen Research & Development has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) requesting approval of its HCV protease inhibitor simeprevir (Olysio) for use with Gilead Sciences' HCV polymerase inhibitor sofosbuvir (Sovaldi) for certain treatment-naive and previously treated genotype 1 hepatitis C patients.
DDW 2014: AbbVie Interferon-free Regimen Cures More than 90% of Hepatitis C Patients
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 12 May 2014 00:00
- Written by Liz Highleyman
AbbVie's all-oral "3D" regimen containing ABT-450, ombitasvir, and dasabuvir, used with or without ribavirin, led to sustained virological response in 90% to 100% of genotype 1a and 1b hepatitis C patients in the Phase 3 PEARL trials, according to data reported at the Digestive Disease Week (DDW 2014) meeting last week in Chicago and in the May 4 online edition of the New England Journal of Medicine.
New Hepatitis C Treatments Highlighted at Digestive Disease Week
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 06 May 2014 00:00
- Written by Liz Highleyman
Direct-acting antiviral agents for hepatitis C were a key theme of Digestive Disease Week 2014, taking place this week in Chicago. While the conference covers all aspects of gastroenterology and hepatology, new treatments that can cure more than 90% of chronic hepatitis C patients with few side effects in as little as 8 to 12 weeks are bringing about a revolution in the field.
More Articles...
- EASL 2014: Idenix Hepatitis C Drugs Look Promising in Early Studies
- Achillion Announces Start of Studies of ACH-3422 and ACH-3102 for Hepatitis C
- EASL 2014: Sofosbuvir + Ribavirin for 24 Weeks Is Highly Effective Against HCV Genotype 4
- AbbVie Requests FDA Approval of Interferon-free "3D" Combo for Hepatitis C
Web Design and Development by